New imaging study could unlock better kidney cancer treatments
NCT ID NCT07179770
First seen Oct 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-phase study is looking at how the drug belzutifan changes a marker called CAIX on kidney cancer cells. Twelve people with advanced clear cell kidney cancer will get a special PET scan before and after four weeks of belzutifan. The goal is to see if belzutifan lowers CAIX levels, which could help design future combination treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belzutifan (Welireg) and 89Zr-DFO-girentuximab (TLX250-CDx)
What this could lead to
If successful, this could help doctors understand how belzutifan affects kidney cancer cells and pave the way for more effective combination therapies.
What could go wrong
This is a very small, early-phase study with only 12 participants, so results may not apply broadly. The main goal is to measure changes on scans, not to treat the cancer directly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.